Kidney (Renal Cell) Cancer
Featured Articles
(Pfizer) Sept 11, 2018 - Merck KGaA, Darmstadt, Germany, and Pfizer Inc. today announced positive top-line results from the pivotal Phase III JAVELIN Renal 101 study evaluating BAVENCIO® (avelumab) in combination with INLYTA® (axitinib), compared with SUTENT® (sunitinib) as initial therapy for patients with advanced renal cell...
Read Article
(Bloomberg) July 26, 2018 - During a call discussing the company’s second-quarter results, Chief Executive Officer Giovanni Caforio said that Bristol-Myers’s combination cancer treatment had failed to secure additional approval from European regulators for use in a form of kidney cancer. Adding new indications for the drugs has been...
Read Article
Latest Articles
September 18, 2018
September 11, 2018
September 07, 2018
September 07, 2018
August 29, 2018
August 29, 2018
August 16, 2018
August 15, 2018
View More
News Commentary
Editor Image
06 Mar, 2018 | by H. Jack West, MD
With the evidence on immune checkpoint inhibitors in many cancer settings being...
View Comment
Editor Image
19 Feb, 2018 | by Winston Wong, PharmD
I lived through and was part of the payer process for many years. It is not a...
View Comment
View More
Featured Videos
There are no videos.
OBR Blog
There are no Kidney (Renal Cell) Cancer blog entries.